Preferred Label : Daratumumab and Hyaluronidase/Dexamethasone/Pomalidomide Regimen;
NCIt synonyms : Pomalidomide-Dexamethasone Plus Daratumumab and Hyaluronidase-fihj; Daratumumab and Hyaluronidase-Pd Regimen; Daratumumab/Recombinant Human Hyaluronidase/Pomalidomide/Dexamethasone Regimen; Daratumumab and Hyaluronidase-fihj/Pomalidomide/Dexamethasone Regimen; Pomalyst-Decadron Plus Darzalex Faspro Regimen; Pomalidomide/Dexamethasone Plus Daratumumab and Hyaluronidase Regimen; Daratumumab and Hyaluronidase-Dexamethasone-Pomalidomide Regimen; Darzalex Faspro/Pomalidomide/Dexamethasone Regimen; Darzalex Faspro/Decadron/Pomalyst; Daratumumab and Hyaluronidase/Pomalidomide/Dexamethasone Regimen; Pomalidomide/Daratumumab and Hyaluronidase/Dexamethasone; Pomalidomide/Daratumumab and Hyaluronidase-fihj/Dexamethasone Regimen; Daratumumab-Hyaluronidase/Pomalidomide/Dexamethasone; Daratumumab/Hyaluronidase-Pomalidomide-Dexamethasone; Daratumumab and Hyaluronidase/Pomalidomide/Low-dose Dexamethasone; Daratumumab/Hyaluronidase-Pd Regimen; Daratumumab Subcutaneous-Pomalidomide-Dexamethasone Regimen; Dara-Pd (Subcutaneous Daratumumab); Darzalex Faspro/Pomalyst/Decadron Regimen; Pomalidomide-Dexamethasone Plus Daratumumab and Hyaluronidase; Darzalex Faspro-Dexamethasone-Pomalidomide; Pomalidomide/Dexamethasone Plus Darzalex Faspro; Daratumumab SC-Pd Regimen; Dara (Daratumumab Subcutaneous)-PD Regimen;
NCIt related terms : Dara-Pd (SC daratumumab);
NCIt definition : A regimen consisting of daratumumab and hyaluronidase, dexamethasone and pomalidomide
that is used for the treatment of plasma cell myeloma.;
NCI Metathesaurus CUI : CL1920751;
Codes from synonyms : 9752;
Origin ID : C201911;
UMLS CUI : C5908241;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
